IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
ONCE News
Archived Headlines
- Renaissance Capital's 2015 US IPO Annual Review 12/18/15
- Novartis-backed GenSight Biologics sets terms for $65 million IPO 10/27/15
- Eye sees more gene therapy: GenSight Biologics files for a $100 million IPO 07/07/15
- Aduro Biotech soars 100% on IPO 04/15/15
- US IPO Market Off to a Slow Start: Renaissance Capital's 1Q 2015 Review 03/31/15
See more
Two biotech IPOs were just acquired for $1+ billion each
Biotechs got a shot in the arm on Monday, with $1+ billion acquisitions of 2015 and 2017 IPOs. Gene therapy biotech Spark Therapeutics spiked 120% on Monday after announcing that it would be acquired by Roche for about $4.8 billion. Its stock closed above $113, a 393% premium to its January 2015 offer price. Spun out of the Children's Hospital of...read more
US IPO Weekly Recap: June kicks off to a slow start with 2 IPO pricings but only one trading
Two IPOs priced in the first week of June; only one has started trading Four companies added to the calendar (including two SPACs) ...read more
US IPO Week Ahead: 2 IPOs in the first week of June; more launches expected
It's a slow start to the typically-active month of June, but that should change soon. Two companies are targeting a combined $158 million in the week ahead. Deals include Taiwan-based live streaming company M17 Entertainment and gene therapy biotech MeiraGTx. ...read more
No IPO in sight: GenSight Biologics withdraws $65 million IPO
GenSight Biologics, which is developing gene therapies for rare retinal diseases, withdrew its plans for an initial public offering on Thursday. It had filed to raise $65 million by offering 4.7 million shares at a price range of $13 to $15. It is the second biotech to withdraw IPO papers in two days, following Bavarian Nordic's (BAVN) withdrawal on Wednesday. Another...read more